Alglucosidase alfa 1.1g/500ml infusion bags
Requires a prescription from a doctor or prescriber
Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Alglucosidase alfa
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Alglucosidase alfa
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Alglucosidase alfa
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Avalglucosidase alfa for treating Pompe disease (TA821)
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
0.4 hours
Mechanism
Alglucosidase alfa is designed to act as an exogenous source of GAA, acting to c…
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
0.4 hours
Volume of distribution
16 mL
* 119 ± 28 mL/kg [40 mg/kg dose]
Elimination
Clearance
4 mL
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 119 ± 28 mL/kg [40 mg/kg dose]
Proteins and enzymes this drug interacts with in the body
PMID:14695532 PMID:18429042 PMID:1856189 PMID:7717400
Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans PMID:29061980
PMID:18817523 PMID:2963003
Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex .
PMID:18817523 PMID:2963003
The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer .
PMID:18817523
This receptor also binds IGF2 .
PMID:18046459
Acts as a positive regulator of T-cell coactivation by binding DPP4 PMID:10900005
ATC A16AB07
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Alglucosidase alfa
Additional database identifiers
Drugs Product Database (DPD)
19883
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4065
GenAtlas
GAA
GeneCards
GAA
GenBank Gene Database
Y00839
GenBank Protein Database
31608
Guide to Pharmacology
2611
UniProt Accession
LYAG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6752
GeneCards
M6PR
UniProt Accession
MPRD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5467
GeneCards
IGF2R
GenBank Gene Database
Y00285
GenBank Protein Database
33055
UniProt Accession
MPRI_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: